Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over 12 months in African children. We therefore assessed a new candidate vaccine for safety and efficacy.

More information Original publication

DOI

10.1016/S0140-6736(21)00943-0

Type

Alumni publications

Publisher

The Lancet

Volume

397

Pages

1809 - 1818

Keywords

malaria vaccine, Burkina Faso, children, randomised controlled trial